Trudeau added that Therakos Photopheresis enjoys a commercial support model that has a high degree of potential hospital account overlap with Mallinckrodt’s INOMAX® (nitric oxide) vasodilator treatment for hypoxic respiratory failure in term and near-term infants. Enclose phrases in quotes.

Therakos™ Cellex™ Photopheresis System; UVADEX™ Methoxsalen, Sterile Solution; Customer Support; Therakos™ Cellex™ Photopheresis System.

INOMAX™ 1-877-KNOWINO (566-9466) Therakos™ 1-877-566-9466. "Outside the U.S., there are a number of open systems, he said. Under Gores’ ownership, Therakos redesigned the manufacturing process to improve product quality and increase production volumes to meet increasing patient demand.
Mallinckrodt to add cancer drug delivering device to its stable via $1.3B purchase of Therakos, Nanoform to test nanoformed drug in humans before year is out, Swiss scientists take sonic approach to targeted drug delivery, Alexion's new, quicker-infusing Ultomiris formula snares FDA nod. Use a + to require a term in results and - to Host Cell Protein Analysis Informs Risk Assessment, Top 20 R&D Spenders among Tool and Tech Companies, DNA Repair Genes May Determine When Huntington’s Symptoms Begin, COVID-19 Drug & Vaccine Candidate Tracker, SARS-CoV-2 Uses a Second Receptor, Neuropilin-1, to Infect Human Cells, Diet High in Flavanol-Rich Foods and Drinks Could Help to Lower Blood Pressure, The Missing Link That Connects Gum Disease to Inflammatory Diseases, Minimal CRISPR-Cas3 System Makes Substantial Deletions, Diagnostic for Detecting Alzheimer’s Earlier Developed, CRISPR Anticancer Tech Aids Immune System Surveillance and Attack, Mouse Model Shows How Oncogenes Cooperate.

Therakos ® Photopheresis is approved by the U.S. Food and Drug Administration for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in persons who have not been responsive to other forms of treatment. Photopheresis platforms are used by more than 350 hospitals and major medical centers in more than 25 countries.

The deal is designed to expand the biopharma’s specialty brands business with the acquired company’s treatment platforms that use patients' immune systems to fight disease. Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year. Theranos (/ ˈ θ ɛr ə n oʊ s /) was a privately held health technology corporation. Copyright © 2020 Genetic Engineering & Biotechnology News.

He said that in terms of M&A, the company is primarily focused on new drugs, but added "if there are certain drug-device combinations that meet our strategic and financial criteria, like the last two that we've done, we're quite happy to do those as well. With roughly 60% of Therakos' revenue in the U.S., Mallinckrodt said it expects to finish fiscal 2015 with net sales of $185 to $195 million, and anticipates “high single-digit growth” from that base going forward, driven primarily by the U.S. market. In the U.S., Therakos Photopheresis is FDA-approved for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who have not been responsive to other forms of treatment. INDICATIONS. Therakos Photopheresis harnesses the power of a patient's own immune system to fight disease," he continued.

Select the NDC to see product information. In December 2012, The Gores Group acquired Therakos, a medical device-drug company, from Ortho Clinical Diagnostics, a former subsidiary of Johnson & Johnson.

That drug/device combination product was acquired in March as part of a $2.3 billion deal.
CELLEX System, according to Mallinckrodt, will particularly benefit from the buyer’s larger hospital presence, regulatory expertise, years of complex drug and device manufacturing, and support of similar medication- technology-service offerings. Mallinckrodt believes that it can expand the indication of the device in the U.S. and expand adoption of the Cellex in hospitals. Gores recruited a management team with more than 20 years of experience in the healthcare space and executed a complex carve-out to establish Therakos as a scalable, stand-alone company in just over a year. Therakos’ Photopheresis® platforms are drug/device systems designed to deliver autologous immune cell therapy through extracorporeal photopheresis (ECP). The information below is about the use of UVADEX ® (methoxsalen) Sterile Solution with the THERAKOS ® UVAR XTS ® or THERAKOS CELLEX® Photopheresis Systems for the treatment of skin conditions associated with Cutaneous T-Cell Lymphoma (CTCL) unresponsive to other types of treatment.. Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too. Learn how your comment data is processed.